Home >> Pharmaceuticals >> Food & Beverage >>

PharmAbcine, Inc. - Product Pipeline Review - 2015

Published: Aug-2015 | Format: PDF | Global Markets Direct | Number of pages: 35 | Code: MRS - 35139

PharmAbcine, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘PharmAbcine, Inc. - Product Pipeline Review - 2015’, provides an overview of the PharmAbcine, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of PharmAbcine, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of PharmAbcine, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of PharmAbcine, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the PharmAbcine, Inc.’s pipeline products

Reasons to buy

- Evaluate PharmAbcine, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of PharmAbcine, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the PharmAbcine, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of PharmAbcine, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of PharmAbcine, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of PharmAbcine, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
PharmAbcine, Inc. Snapshot 5
PharmAbcine, Inc. Overview 5
Key Information 5
Key Facts 5
PharmAbcine, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
PharmAbcine, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
PharmAbcine, Inc. - Pipeline Products Glance 11
PharmAbcine, Inc. - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
PharmAbcine, Inc. - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
PharmAbcine, Inc. - Drug Profiles 15
TTAC-0001 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
PMC-001 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
PMC-002 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
PMC-201 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Monoclonal Antibody to Antagonize c-Met for Cancer and Inflammatory Disorders 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Monoclonal Antibody to Antagonize EGFR for Cancer and Inflammatory Disorders 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Monoclonal Antibody to Antagonize HER2 for Cancer and Inflammatory Disorders 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Monoclonal Antibody to Antagonize IGFR-1 for Cancer and Inflammatory Disorders 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Monoclonal Antibody to Antagonize VEGFR-1 for Cancer and Inflammatory Disorders 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Monoclonal Antibody to Antagonize VEGFR-3 for Cancer and Inflammatory Disorders 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Monoclonal Antibody to Inhibit DLL4 for Cancer and Inflammatory Disorders 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Monoclonal Antibody to Inhibit EPCAM for Cancer and Inflammatory Disorders 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Monoclonal Antibody to Target CD-20 for Cancer and Inflammatory Disorders 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
PharmAbcine, Inc. - Pipeline Analysis 28
PharmAbcine, Inc. - Pipeline Products by Target 28
PharmAbcine, Inc. - Pipeline Products by Molecule Type 30
PharmAbcine, Inc. - Pipeline Products by Mechanism of Action 31
PharmAbcine, Inc. - Recent Pipeline Updates 32
PharmAbcine, Inc. - Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 34
Disclaimer 35

List of Tables
PharmAbcine, Inc., Key Information 5
PharmAbcine, Inc., Key Facts 5
PharmAbcine, Inc. - Pipeline by Indication, 2015 7
PharmAbcine, Inc. - Pipeline by Stage of Development, 2015 9
PharmAbcine, Inc. - Monotherapy Products in Pipeline, 2015 10
PharmAbcine, Inc. - Phase II, 2015 11
PharmAbcine, Inc. - Phase I, 2015 12
PharmAbcine, Inc. - Preclinical, 2015 13
PharmAbcine, Inc. - Discovery, 2015 14
PharmAbcine, Inc. - Pipeline by Target, 2015 29
PharmAbcine, Inc. - Pipeline by Molecule Type, 2015 30
PharmAbcine, Inc. - Pipeline Products by Mechanism of Action, 2015 31
PharmAbcine, Inc. - Recent Pipeline Updates, 2015 32
PharmAbcine, Inc., Other Locations 33

List of Figures
PharmAbcine, Inc. - Pipeline by Top 10 Indication, 2015 7
PharmAbcine, Inc. - Pipeline by Stage of Development, 2015 9
PharmAbcine, Inc. - Monotherapy Products in Pipeline, 2015 10
PharmAbcine, Inc. - Pipeline by Top 10 Target, 2015 28
PharmAbcine, Inc. - Pipeline by Top 10 Molecule Type, 2015 30
PharmAbcine, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 31

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode
Single User | $(USD)1500 View Pricing